However, the exact molecular target remains unidentified, and efficacy has not been demonstrated in humans
Clin Cancer Res 17:63896397 ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W (2009) A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
Every batch is third-party tested for identity, potency, sterility, and endotoxin before release
(PubMed) Laclaustra M, Stranges S, Navas-Acien A, Ordovas JM, Guallar E
In the landmark study that introduced it, published in Cell Metabolism (Lee et al., 2015), researchers showed that MOTS-c regulates insulin sensitivity and metabolic homeostasis through the AMPK pathway, and that treatment prevented diet-induced obesity and insulin resistance in animal models
Borst, P